Oak Street Health, Inc. (NYSE:OSH – Get Rating) insider Geoffrey M. Price sold 60,000 shares of the business’s stock in a transaction on Tuesday, April 19th. The shares were sold at an average price of $24.91, for a total transaction of $1,494,600.00. Following the sale, the insider now directly owns 2,073,270 shares of the company’s stock, valued at approximately $51,645,155.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of NYSE OSH traded down $2.13 during mid-day trading on Wednesday, hitting $23.13. 1,306,651 shares of the company’s stock traded hands, compared to its average volume of 3,300,751. The company’s 50-day moving average is $22.41 and its two-hundred day moving average is $29.06. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.06 and a quick ratio of 2.06. The company has a market capitalization of $5.57 billion, a P/E ratio of -12.73 and a beta of 2.18. Oak Street Health, Inc. has a 1 year low of $13.72 and a 1 year high of $65.22.
Oak Street Health (NYSE:OSH – Get Rating) last announced its earnings results on Monday, February 28th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The business had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $389.79 million. Oak Street Health had a negative net margin of 28.57% and a negative return on equity of 231.28%. The firm’s quarterly revenue was up 58.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.40) earnings per share. Equities analysts anticipate that Oak Street Health, Inc. will post -1.95 EPS for the current fiscal year.
Several research analysts recently weighed in on OSH shares. SVB Leerink upped their target price on shares of Oak Street Health from $17.00 to $23.00 and gave the stock a “market perform” rating in a report on Wednesday, March 2nd. Raymond James dropped their target price on shares of Oak Street Health from $60.00 to $35.00 and set an “outperform” rating for the company in a report on Tuesday, January 18th. Morgan Stanley upped their target price on shares of Oak Street Health from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 2nd. UBS Group started coverage on shares of Oak Street Health in a report on Wednesday. They issued a “neutral” rating and a $26.00 target price for the company. Finally, Cowen raised shares of Oak Street Health from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $25.00 to $30.00 in a report on Thursday, March 17th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Oak Street Health presently has an average rating of “Buy” and a consensus target price of $42.13.
Oak Street Health Company Profile (Get Rating)
Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas.
- Get a free copy of the StockNews.com research report on Oak Street Health (OSH)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Oak Street Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oak Street Health and related companies with MarketBeat.com's FREE daily email newsletter.